Literature DB >> 16254103

Immunohistochemical analysis of desmoid tumours.

A Leithner1, M Gapp, R Radl, A Pascher, P Krippl, K Leithner, R Windhager, A Beham.   

Abstract

BACKGROUND/AIMS: Although the standard treatment for desmoid tumours is complete surgical resection with wide margins, the optimal adjuvant treatment for recurrent or inoperable disease is unclear, often being based on sporadic immunohistochemical reports with a low number of cases. Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens.
METHODS: One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0-83) with desmoid tumours (46 extra-abdominal, 21 abdominal, 13 intra-abdominal) were tested for oestrogen receptors alpha and beta, progesterone and androgen receptors, and somatostatin, in addition to HER2, cathepsin D, Ki-67, and c-KIT by immunohistochemistry.
RESULTS: All samples were negative for oestrogen receptor alpha, HER2, and the progesterone receptor. Positive staining for the androgen receptor was found in six extra-abdominal cases. Staining for oestrogen receptor beta was positive in four extra-abdominal, two abdominal, and one intra-abdominal case. Staining for somatostatin was positive in six extra-abdominal, two abdominal, and one intra-abdominal case, and staining for cathepsin D was positive in all cases. Positive staining for Ki-67 was found in 14 extra-abdominal, three abdominal, and three intra-abdominal cases. C-KIT was detectable in one abdominal case only.
CONCLUSIONS: The data from this immunohistochemical study show that the published effects of antioestrogens and imatinib mesylate in the treatment of aggressive fibromatoses may not be attributable to oestrogen receptor alpha or c-KIT expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254103      PMCID: PMC1770757          DOI: 10.1136/jcp.2005.026278

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  36 in total

1.  Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma.

Authors:  C D Morris; R Gorlick; G Huvos; G Heller; P A Meyers; J H Healey
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

2.  Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patients.

Authors:  W M Brueckl; J M Preuss; A Wein; A Jung; T Brabletz; R Pflüger; G H Wiest; C Wolfl; T Kirchner; E G Hahn; W Hohenberger; K Günther
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

3.  Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors.

Authors:  A Hoos; J J Lewis; C R Antonescu; M E Dudas; L Leon; J M Woodruff; M F Brennan; C Cordon-Cardo
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

4.  Extraabdominal desmoid tumor. A study of 83 cases.

Authors:  G Pignatti; G Barbanti-Bròdano; D Ferrari; F Gherlinzoni; F Bertoni; P Bacchini; E Barbieri; A Giunti; M Campanacci
Journal:  Clin Orthop Relat Res       Date:  2000-06       Impact factor: 4.176

5.  Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature.

Authors:  D W Easter; N A Halasz
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

6.  The desmoid tumor. III. A biochemical and genetic analysis.

Authors:  P Häyry; J J Reitamo; R Vihko; O Jänne; T M Scheinin; S Tötterman; J Ahonen; R Norio; A Alanko
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

7.  Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis.

Authors:  Umio Yamaguchi; Tadashi Hasegawa; Taizo Masuda; Shigeki Sekine; Akira Kawai; Hirokazu Chuman; Tadakazu Shimoda
Journal:  Virchows Arch       Date:  2004-06-30       Impact factor: 4.064

8.  Aggressive fibromatosis.

Authors:  B A Alman; M J Goldberg; S P Naber; T Galanopoulous; H N Antoniades; H J Wolfe
Journal:  J Pediatr Orthop       Date:  1992-01       Impact factor: 2.324

9.  Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases.

Authors:  Jan Heidemann; Hitoshi Ogawa; Mary F Otterson; Vinod B Shidham; David G Binion
Journal:  Dis Colon Rectum       Date:  2004-01-14       Impact factor: 4.585

10.  Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.

Authors:  T De Pas; L Bodei; G Pelosi; F De Braud; G Villa; R Capanna; G Paganelli
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

View more
  18 in total

1.  Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.

Authors:  Justin M M Cates; Jennifer O Black; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin
Journal:  Hum Pathol       Date:  2012-04-18       Impact factor: 3.466

2.  Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.

Authors:  Daniel Robert Quast; Ralph Schneider; Emanuel Burdzik; Steffen Hoppe; Gabriela Möslein
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

3.  Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors.

Authors:  Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates
Journal:  Cancer Sci       Date:  2012-11-15       Impact factor: 6.716

4.  Desmoid tumour in familial adenomatous polyposis patients: responses to treatments.

Authors:  Thibault Desurmont; Jérémie H Lefèvre; Conor Shields; Chrystelle Colas; Emmanuel Tiret; Yann Parc
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

Review 5.  The enigma of desmoid tumors.

Authors:  Scott Okuno
Journal:  Curr Treat Options Oncol       Date:  2006-11

6.  Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.

Authors:  Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Peter Hohenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-19       Impact factor: 9.236

Review 7.  Desmoid tumors: clinical features and treatment options for advanced disease.

Authors:  Bernd Kasper; Philipp Ströbel; Peter Hohenberger
Journal:  Oncologist       Date:  2011-04-08

8.  A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.

Authors:  Jae-Cheol Jo; Yong Sang Hong; Kyu-Pyo Kim; Jae-Lyun Lee; Jeeyun Lee; Young Suk Park; Sun Young Kim; Jin-Sook Ryu; Jong-Seok Lee; Tae Won Kim
Journal:  Invest New Drugs       Date:  2014-01-16       Impact factor: 3.850

9.  Pedicled TRAM Flap in Presence of Desmoid Tumor of the Rectus Sheath; a Case Report.

Authors:  Ashraf Khater
Journal:  Indian J Surg Oncol       Date:  2015-07-04

10.  Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.

Authors:  Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Lothar R Pilz; Ludwig G Strauss; Christos Sachpekidis; Peter Hohenberger
Journal:  Biomed Res Int       Date:  2013-05-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.